Scarica l'app Stockscreener
13.56
1.74%
-0.24
Dopo l'orario di chiusura:
13.72
0.16
+1.18%
Oculis Holding Ag Borsa (OCS) Ultime notizie
Enterprise value to revenue forward of Oculis Holding AG – SWB:CR5 - TradingView
Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings - TradingView
Oculis stock gains after FDA trial design agreement - Investing.com
Oculis to present updates on late-stage eye dis... - Pluang
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - The Manila Times
Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference - Quiver Quantitative
Oculis spotlights late-stage eye drugs at Piper Sandler event - Stock Titan
Trading the Move, Not the Narrative: (OCS) Edition - Stock Traders Daily
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway - TipRanks
Oculis Holding AG Actuals & Estimates (NASDAQ:OCS) - TradingView
Oculis Holding AG Warrants (OCSAW) See Upward Momentum Amid Modest GainsSign of Strength - dars.gov.et
Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029 - Stock Titan
OCS Forecast — Price Target — Prediction for 2027 - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
OCSOculis Holding AG Revenue Breakdown - Finviz
Oculis Holding AG (OCSAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(OCS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCSAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCSAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCSAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCSAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCSAW) Institutional Confidence - TradingKey
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - GlobeNewswire
Oculis : Minutes of the 2026 Annual General Meeting of Shareholders - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect - ACCESS Newswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times
Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative
Experimental eye drug Privosegtor aims to protect vision in optic neuritis - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):